Display options
Cite
El Achi H, Dupont E, Paul S, et al. CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. Cancers (Basel). 2020;12(11)doi: 10.3390/cancers12113087.
El Achi, H., Dupont, E., Paul, S., & Khoury, J. D. (2020). CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. Cancers, 12(11), . https://doi.org/10.3390/cancers12113087
El Achi, Hanadi, et al. "CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies." Cancers vol. 12,11 (2020). doi: https://doi.org/10.3390/cancers12113087
El Achi H, Dupont E, Paul S, Khoury JD. CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. Cancers (Basel). 2020 Oct 23;12(11). doi: 10.3390/cancers12113087. PMID: 33113953; PMCID: PMC7690688.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2020 Oct 23;12(11). doi: 10.3390/cancers12113087.

CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies.

Cancers

Hanadi El Achi, Edouard Dupont, Shilpa Paul, Joseph D Khoury

Affiliations

  1. Department of Pathology and Laboratory Medicine, The University of Texas at Houston, Houston, TX 77030, USA.
  2. Faculty of Pharmacy of Paris, Paris Descartes University, 75270 Paris, France.
  3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
  4. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

PMID: 33113953 PMCID: PMC7690688 DOI: 10.3390/cancers12113087

Abstract

CD123, the α chain of the interleukin 3 receptor, is a cytokine receptor that is overexpressed in multiple hematolymphoid neoplasms, including acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, acute lymphoblastic leukemia, hairy cell leukemia, and systemic mastocytosis. Importantly, CD123 expression is upregulated in leukemic stem cells relative to non-neoplastic hematopoietic stem cells, which makes it a useful diagnostic and therapeutic biomarker in hematologic malignancies. Varying levels of evidence have shown that CD123-targeted therapy represents a promising therapeutic approach in several cancers. Tagraxofusp, an anti-CD123 antibody conjugated to a diphtheria toxin, has been approved for use in patients with blastic plasmacytoid dendritic cell neoplasm. Multiple clinical trials are investigating the use of various CD123-targeting agents, including chimeric antigen receptor-modified T cells (expressing CD123, monoclonal antibodies, combined CD3-CD123 dual-affinity retargeting antibody therapy, recombinant fusion proteins, and CD123-engager T cells. In this review, we provide an overview of laboratory techniques used to evaluate and monitor CD123 expression, describe the strengths and limitations of detecting this biomarker in guiding therapy decisions, and provide an overview of the pharmacologic principles and strategies used in CD123-targeted therapies.

Keywords: CD123; biomarker; flow cytometry; immunohistochemistry; targeted therapy

References

  1. Life Sci. 2015 Feb 1;122:59-64 - PubMed
  2. Leukemia. 2000 Apr;14(4):576-85 - PubMed
  3. Cell Stem Cell. 2013 Mar 7;12(3):329-41 - PubMed
  4. Br J Haematol. 2010 Mar;148(6):879-89 - PubMed
  5. Cell Rep. 2014 Jul 24;8(2):410-9 - PubMed
  6. Nat Commun. 2018 Sep 12;9(1):3694 - PubMed
  7. Haematologica. 2015 Feb;100(2):223-30 - PubMed
  8. Blood. 2014 Feb 20;123(8):1218-28 - PubMed
  9. Cytometry B Clin Cytom. 2019 Mar;96(2):134-142 - PubMed
  10. Blood Cancer J. 2017 Jun 2;7(6):e567 - PubMed
  11. Br J Haematol. 2014 Sep;166(6):862-74 - PubMed
  12. PLoS One. 2020 Jul 20;15(7):e0236124 - PubMed
  13. Leukemia. 2016 Apr;30(4):914-8 - PubMed
  14. J Leukoc Biol. 2015 Jan;97(1):49-59 - PubMed
  15. Leuk Lymphoma. 2019 Nov;60(11):2606-2621 - PubMed
  16. J Hematol Oncol. 2015 Feb 28;8:18 - PubMed
  17. Haematologica. 2019 Apr;104(4):749-755 - PubMed
  18. Int J Mol Sci. 2019 Nov 10;20(22): - PubMed
  19. Am J Hum Genet. 1993 Nov;53(5):1146-53 - PubMed
  20. Protein Eng Des Sel. 2012 Oct;25(10):561-9 - PubMed
  21. Leuk Lymphoma. 2008 Mar;49(3):543-53 - PubMed
  22. Mol Ther. 2015 Jan;23(1):171-8 - PubMed
  23. Biochem Biophys Res Commun. 1995 Mar 8;208(1):360-7 - PubMed
  24. Oncoimmunology. 2018 Jul 30;7(9):e1472195 - PubMed
  25. Am J Pathol. 2002 Feb;160(2):585-96 - PubMed
  26. Blood. 1997 Feb 1;89(3):842-52 - PubMed
  27. Haematologica. 2015 Jul;100(7):914-26 - PubMed
  28. Curr Hematol Malig Rep. 2018 Dec;13(6):477-483 - PubMed
  29. Blood. 2014 Jul 17;124(3):385-92 - PubMed
  30. Blood. 2014 Apr 10;123(15):2343-54 - PubMed
  31. Front Oncol. 2019 Dec 03;9:1358 - PubMed
  32. Chin Med J (Engl). 2010 Aug 5;123(15):2034-7 - PubMed
  33. Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11872-7 - PubMed
  34. Immunol Rev. 2012 Nov;250(1):277-302 - PubMed
  35. Stem Cells. 1998;16(5):301-13 - PubMed
  36. Clin Cancer Res. 2018 Feb 1;24(3):521-531 - PubMed
  37. Appl Immunohistochem Mol Morphol. 2013 May;21(3):212-7 - PubMed
  38. Blood. 2013 Oct 31;122(18):3138-48 - PubMed
  39. Clin Cancer Res. 2006 Feb 15;12(4):1284-91 - PubMed
  40. Blood Adv. 2017 Jun 20;1(15):1067-1079 - PubMed
  41. Blood Rev. 1991 Sep;5(3):193-203 - PubMed
  42. N Engl J Med. 2017 Mar 9;376(10):917-927 - PubMed
  43. Exp Hematol. 2019 Jun;74:52-63.e3 - PubMed
  44. PLoS One. 2015 Sep 16;10(9):e0128998 - PubMed
  45. Am J Clin Pathol. 2011 Oct;136(4):625-30 - PubMed
  46. Haematologica. 2018 Oct;103(10):1720-1729 - PubMed
  47. Science. 2018 Mar 23;359(6382):1361-1365 - PubMed
  48. Curr Hematol Malig Rep. 2018 Dec;13(6):446-454 - PubMed
  49. Cell Stem Cell. 2009 Jul 2;5(1):31-42 - PubMed
  50. Blood Cancer J. 2019 Jan 15;9(2):6 - PubMed
  51. Nat Commun. 2018 Jan 26;9(1):386 - PubMed
  52. Cytokine Growth Factor Rev. 2013 Jun;24(3):189-201 - PubMed
  53. Blood. 2017 Apr 27;129(17):2395-2407 - PubMed
  54. Int J Hematol. 2019 May;109(5):539-544 - PubMed
  55. Immunol Rev. 2019 Jul;290(1):39-59 - PubMed
  56. Leukemia. 2014 Aug;28(8):1596-605 - PubMed
  57. Sci Transl Med. 2015 May 27;7(289):289ra82 - PubMed
  58. Expert Rev Clin Pharmacol. 2019 Oct;12(10):941-946 - PubMed
  59. Exp Hematol. 1999 Dec;27(12):1746-56 - PubMed
  60. Trends Pharmacol Sci. 2012 Jan;33(1):35-41 - PubMed
  61. Blood. 2016 Jan 7;127(1):122-31 - PubMed
  62. Haematologica. 2001 Dec;86(12):1261-9 - PubMed
  63. Br J Haematol. 2019 Aug;186(4):538-548 - PubMed
  64. Biomark Res. 2014 Feb 10;2(1):4 - PubMed
  65. Leukemia. 2019 Oct;33(10):2466-2480 - PubMed
  66. Haematologica. 2020 Apr 2;: - PubMed
  67. Blood. 2016 Apr 14;127(15):1863-9 - PubMed
  68. N Engl J Med. 2019 Apr 25;380(17):1628-1637 - PubMed
  69. Blood Adv. 2018 Apr 24;2(8):848-858 - PubMed
  70. Br J Haematol. 2009 Feb;144(3):376-87 - PubMed
  71. Cancer Cell. 2009 Oct 6;16(4):309-23 - PubMed
  72. Blood. 2011 Apr 28;117(17):4542-51 - PubMed
  73. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e349-e358 - PubMed
  74. Curr Hematol Malig Rep. 2019 Oct;14(5):368-375 - PubMed
  75. Leukemia. 2014 Nov;28(11):2213-21 - PubMed
  76. Mol Ther. 2016 Sep 29;24(9):1615-26 - PubMed
  77. Histopathology. 2020 Aug;77(2):262-274 - PubMed
  78. Haematologica. 2004 Mar;89(3):303-8 - PubMed
  79. Br J Haematol. 2010 Sep;150(5):574-86 - PubMed
  80. Blood. 2002 Oct 15;100(8):2980-8 - PubMed
  81. Leuk Lymphoma. 2015 May;56(5):1406-15 - PubMed
  82. Mol Cancer Ther. 2018 Feb;17(2):554-564 - PubMed
  83. Am J Surg Pathol. 2019 Oct;43(10):1429-1437 - PubMed
  84. Cancers (Basel). 2019 Sep 12;11(9): - PubMed
  85. Am J Hematol. 2013 Dec;88(12):1055-61 - PubMed
  86. Blood. 2014 Apr 17;123(16):2540-9 - PubMed
  87. Leukemia. 2017 Dec;31(12):2652-2660 - PubMed
  88. Cancer Discov. 2017 Oct;7(10):1154-1167 - PubMed
  89. Stem Cells. 1999;17(5):265-72 - PubMed
  90. Clin Lymphoma Myeloma Leuk. 2020 Oct 8;: - PubMed
  91. Cancer Res. 2004 Apr 15;64(8):2817-24 - PubMed
  92. Int J Hematol. 2014 Jul;100(1):60-9 - PubMed
  93. Nat Rev Drug Discov. 2019 Aug;18(8):585-608 - PubMed

Publication Types

Grant support